U.S. markets open in 4 hours 33 minutes
  • S&P Futures

    4,263.25
    -17.75 (-0.41%)
     
  • Dow Futures

    33,600.00
    -118.00 (-0.35%)
     
  • Nasdaq Futures

    13,520.50
    -57.25 (-0.42%)
     
  • Russell 2000 Futures

    2,005.90
    -11.00 (-0.55%)
     
  • Crude Oil

    89.95
    -2.14 (-2.32%)
     
  • Gold

    1,800.10
    -15.40 (-0.85%)
     
  • Silver

    20.47
    -0.23 (-1.13%)
     
  • EUR/USD

    1.0206
    -0.0051 (-0.50%)
     
  • 10-Yr Bond

    2.8490
    0.0000 (0.00%)
     
  • Vix

    20.73
    +0.53 (+2.62%)
     
  • GBP/USD

    1.2071
    -0.0068 (-0.56%)
     
  • USD/JPY

    133.3660
    -0.1140 (-0.09%)
     
  • BTC-USD

    24,054.10
    -615.65 (-2.50%)
     
  • CMC Crypto 200

    571.65
    +0.37 (+0.06%)
     
  • FTSE 100

    7,515.93
    +15.04 (+0.20%)
     
  • Nikkei 225

    28,871.78
    +324.80 (+1.14%)
     

Why BioNTech Stock Advanced Today

·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Shares of the German coronavirus vaccine developer BioNTech (NASDAQ: BNTX) have climbed by more than 5.6% as of 12:07 p.m. ET on Thursday due to news released Wednesday evening that the U.S. government had signed a new supply agreement for 105 million doses of its Comirnaty jab. The company and its collaborator, Pfizer (NYSE: PFE), will be paid $3.2 billion when the government receives the doses it ordered, and the deal also includes the option to purchase another 195 million doses if needed. The supply agreement also implies a price per dose that's 27% higher than what was negotiated in prior agreements.